Edward White
Edward P. White is the managing director, senior biotechnology analyst, at H.C. Wainwright & Co., where his research coverage focus is on small to mid-cap life sciences companies. He formerly was a senior biotech equity research analyst at FBR & Co. Prior to FBR, he worked in several healthcare equity research groups, including Deutsche Bank Securities and BMO Capital Markets. He also worked for six years as a Senior Buyside Healthcare Research Analyst at Mitsubishi UFJ Trust.
Recent Articles
Biopharma Gains Another Shot on Goal With IND Approval 01/26/2023
The firm's CD19- and CD3-targeting monoclonal antibody is now cleared for evaluation in a Phase I clinical trial, noted an H.C. Wainwright & Co. report.
Biopharma Creating COVID Drug Gets US$8.2M From the DOD 01/24/2023
This tranche, other cash and cash equivalents, and current cash flow are sufficient to get the developer of immunotherapeutics through 2023, noted an H.C. Wainwright & Co. report.
Biopharma Asks for Emergent Use in US of New COVID Drug 09/29/2022
The requested approval is specifically for critically ill patients, a population for which the U.S. Food and Drug Administration granted the therapeutic fast track status, noted an H.C. Wainwright & Co. report.
Recent Quotes
"RLMD has approximately $15.1M in cash and cash equivalents on its balance sheet, which should fund operations through the end of this calendar year."
—
Edward White, FBR & Co.
(2/12/16)
more >
"RLMD reaffirmed 2016 timelines and developmental goals for its product pipeline."
—
Edward White, FBR & Co.
(1/26/16)
more >
"The results from the MAD study confirm the safety and tolerability of RMLD's drug."
—
Edward White, FBR & Co.
(1/4/16)
more >
"We maintain our Buy rating on CVM, which has more than $14M on its balance sheet."
—
Edward White, Laidlaw & Company
(11/3/14)
more >
"Photos of RXII's treated patients showed significant improvement."
—
Edward White, Laidlaw & Company
(10/8/14)
more >
"CVM's Multikine has multiple applications, any of which could lead to significant market opportunities."
—
Edward White, Laidlaw & Company
(9/24/14)
more >
"RXII's plan to restructure the 1301 study cohorts is a strong positive."
—
Edward White, Laidlaw & Company
(9/11/14)
more >
"RXII should have preliminary Phase 2a trial data by end of September."
—
Edward White, Laidlaw & Company
(9/3/14)
more >
